These findings indicate that a BMP4-activating therapy has the potential to enhance tumor growth in patients bearing tumors with low or no SMAD4 activity, consistent with previous reports in colorectal cancer [62] and pancreatic cancer [63]. Here, SMAD4 is linked to pancreatic neoplasm.